<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(1)</volume><submitter>Liu Z</submitter><pubmed_abstract>Systemic Lupus Erythematosus (SLE) and pemphigus are two representative autoimmune diseases driven by pathogenic autoantibody systemically and organ-specifically, respectively. Given the involvement of antibody in the pathogenesis, B cells are inclined to differentiate and function in an abnormal activation model. Here we defined a unique CD19&lt;sup>hi&lt;/sup> B cell population existing in the periphery of SLE and pemphigus patients as well as in human tonsils. CD19&lt;sup>hi&lt;/sup> B cells could be induced in vitro after co-culturing fully activated CD4&lt;sup>+&lt;/sup> T cells with autologous B cells. They expressed high levels of HLA-DR, IgG, IgM and multiple ligands of costimulatory molecules with the capacity to produce extra IgG and IgM. Transcirptome assay revealed that genes involved in B-cell activation and differentiation were up-regulated in CD19&lt;sup>hi&lt;/sup> B cells. Antibody blockade experiments showed that the interactions between costimulatory molecules contributed to CD19&lt;sup>hi&lt;/sup> B-cell generation and IgG/IgM production. What is more, frequencies of peripheral CD19&lt;sup>hi&lt;/sup> B cells from SLE and pemphigus patients were correlated with serum total IgG and IgM, but not with autoantigen-specific antibodies and disease severity. Therefore, our investigation demonstrates that CD19&lt;sup>hi&lt;/sup> B cells might contain B cell precursors for terminal differentiation and contribute to total IgG/IgM production in human autoimmune diseases.</pubmed_abstract><journal>Scientific reports</journal><pagination>13921</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5655037</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Peripheral CD19&lt;sup>hi&lt;/sup> B cells exhibit activated phenotype and functionality in promoting IgG and IgM production in human autoimmune diseases.</pubmed_title><pmcid>PMC5655037</pmcid><pubmed_authors>Zheng J</pubmed_authors><pubmed_authors>Liu Z</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Zeng W</pubmed_authors><pubmed_authors>Pan M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Peripheral CD19&lt;sup>hi&lt;/sup> B cells exhibit activated phenotype and functionality in promoting IgG and IgM production in human autoimmune diseases.</name><description>Systemic Lupus Erythematosus (SLE) and pemphigus are two representative autoimmune diseases driven by pathogenic autoantibody systemically and organ-specifically, respectively. Given the involvement of antibody in the pathogenesis, B cells are inclined to differentiate and function in an abnormal activation model. Here we defined a unique CD19&lt;sup>hi&lt;/sup> B cell population existing in the periphery of SLE and pemphigus patients as well as in human tonsils. CD19&lt;sup>hi&lt;/sup> B cells could be induced in vitro after co-culturing fully activated CD4&lt;sup>+&lt;/sup> T cells with autologous B cells. They expressed high levels of HLA-DR, IgG, IgM and multiple ligands of costimulatory molecules with the capacity to produce extra IgG and IgM. Transcirptome assay revealed that genes involved in B-cell activation and differentiation were up-regulated in CD19&lt;sup>hi&lt;/sup> B cells. Antibody blockade experiments showed that the interactions between costimulatory molecules contributed to CD19&lt;sup>hi&lt;/sup> B-cell generation and IgG/IgM production. What is more, frequencies of peripheral CD19&lt;sup>hi&lt;/sup> B cells from SLE and pemphigus patients were correlated with serum total IgG and IgM, but not with autoantigen-specific antibodies and disease severity. Therefore, our investigation demonstrates that CD19&lt;sup>hi&lt;/sup> B cells might contain B cell precursors for terminal differentiation and contribute to total IgG/IgM production in human autoimmune diseases.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Oct</publication><modification>2026-05-03T08:02:36.01Z</modification><creation>2019-03-27T02:59:47Z</creation></dates><accession>S-EPMC5655037</accession><cross_references><pubmed>29066741</pubmed><doi>10.1038/s41598-017-14089-2</doi></cross_references></HashMap>